Alumis recently reported positive topline Phase 3 ONWARD1 and ONWARD2 results for its oral TYK2 inhibitor envudeucitinib in ...

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

Assessing disease severity in younger patients remains complex because adult scoring tools may underestimate the disease ...

German registry data suggest apremilast monotherapy improves psoriasis severity and quality of life over 12 months, with ...

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after a pair of positive phase 3 trials. The South San Francisco biotech said ...

Could investing in the pharmaceutical giant pay off over the next five years? I think so, and here is why. AbbVie has a ...

True, Novo Nordisk is making progress in this field. It recently earned approval for an oral formulation of Wegovy, which ...

Alumis, Aktis Oncology, and W.R. Berkley saw significant insider buying last week. There were a handful of other notable ...

Alumis Inc. (NASDAQ:ALMS) is among the 14 best booming stocks to buy right now. On January 9, HC Wainwright & Co.

India's leading drugmaker, Sun Pharma, is contemplating a $10 billion acquisition of US-based women's health specialist, ...

Following rusfertide’s triumphant Phase III trial last year, Protagonist must decide how involved to be in future development ...

India's largest drugmaker, Sun Pharma, is considering a major acquisition. The company is evaluating the purchase of US-based ...